Bio-Rad Announces Pricing of Private Offering of $200 Million of Senior Subordinated Notes
13 Diciembre 2004 - 6:11PM
PR Newswire (US)
Bio-Rad Announces Pricing of Private Offering of $200 Million of
Senior Subordinated Notes HERCULES, Calif., Dec. 13
/PRNewswire-FirstCall/ -- Bio-Rad Laboratories, Inc. (AMEX: BIO;
BIOb), a multinational manufacturer and distributor of life science
research products and clinical diagnostics, announced that it has
agreed to sell $200 million aggregate principal amount of its 6
1/8% Senior Subordinated Notes due 2014 in a private offering. The
Company intends to close the transaction on December 21, 2004. The
Company intends to use the proceeds for working capital and general
corporate purposes, which may include acquisitions. The new Senior
Subordinated Notes have not been registered under the Securities
Act of 1933, as amended, or applicable state securities laws, and
will be offered only to qualified institutional buyers in reliance
on Rule 144A and in offshore transactions pursuant to Regulation S
under the Securities Act of 1933, as amended. Unless so registered,
the new Senior Subordinated Notes may not be offered or sold in the
United States except pursuant to an exemption from the registration
requirements of the Securities Act and applicable state securities
laws. This press release shall not constitute an offer to sell or
the solicitation of an offer to buy these securities, nor shall
there be any sale of these securities in any state in which such
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state.
Various statements made within this press release may constitute
"forward- looking statements" for purposes of the Securities and
Exchange Commission's "safe harbor" provisions under the Private
Securities Litigation Reform Act of 1995 and Rule 3b-6 under the
Securities Exchange Act of 1934. The forward- looking statements
contained herein involve risks and uncertainties that could cause
results to differ materially from the Company's expectations.
DATASOURCE: Bio-Rad Laboratories, Inc. CONTACT: Christine Tsingos,
Vice President and Chief Financial Officer, or Ron Hutton,
Treasurer, both of Bio-Rad Laboratories, Inc., +1-510-724-7000, or
Web site: http://www.bio-rad.com/
Copyright